The docetaxel polymeric form and its antitumor activity


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

A new pharmaceutical form of the antitumor drug docetaxel (Dtx) has been developed based on a biodegradable copolymer of lactic and glycolic acids (PLGA 50/50). This form was constituted of polymeric particles (250 to 300 nm in size) and was highly active against mouse mammary adenocarcinoma (Ca755) and human breast adenocarcinoma (MCF-7Wt) cell lines. The results of the in vivo studies carried out on the C57Bl/6 female mice line showed an increase in the life span of the animals treated with the polymeric particles. Furthermore, the polymeric drug at a dose of 10 mg/kg and the drug substance at a dose of 20 mg/kg manifested a similar effect. At the same time, the acute toxicity of the Dtx polymeric form was 2.3 times lower than that of the drug substance.

作者简介

E. Nikolskaya

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149

O. Zhunina

JSC Russian Research Center for Molecular Diagnostics and Therapy

编辑信件的主要联系方式.
Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149

N. Yabbarov

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149

O. Tereshchenko

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149

A. Godovannyy

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149

N. Gukasova

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149

E. Severin

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
俄罗斯联邦, Moscow, 117149


版权所有 © Pleiades Publishing, Ltd., 2017
##common.cookie##